Golimumab: Clinical update on its use for ulcerative colitis

D. Gilardi, G. Fiorino, M. Allocca, I. Bravatà, Silvio Danese

Research output: Contribution to journalArticlepeer-review


Monoclonal antibodies directed against tumor necrosis factor alpha (anti-TNF-α agents) have dramatically changed the therapeutical approach to inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis. A new anti-TNF drug, golimumab, has recently been approved for patients with moderate to severe ulcerative colitis. Its efficacy has been demonstrated by preclinical and clinical studies and the drug showed an efficacy and safety profile in line with the other anti-TNF agents, such as infliximab and adalimumab. This review gives an overview on golimumab in the treatment of moderate to severe ulcerative colitis.

Original languageEnglish
Pages (from-to)171-184
Number of pages14
JournalDrugs of Today
Issue number3
Publication statusPublished - Mar 1 2015


  • Anti-TNF
  • Golimumab
  • Inflammatory bowel disease
  • Ulcerative colitis

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Medicine(all)


Dive into the research topics of 'Golimumab: Clinical update on its use for ulcerative colitis'. Together they form a unique fingerprint.

Cite this